Laddar...
Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells
Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) is the first choice of treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, single agent usually has limited efficacy due to heterogeneous resistant mechanisms of canc...
Sparad:
| I publikationen: | Oncotarget |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Impact Journals LLC
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5893260/ https://ncbi.nlm.nih.gov/pubmed/29662665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24814 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|